Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NEKTAR THERAPEUTICS

(NKTR)
  Report
Delayed Quote. Delayed Nasdaq - 10/26 04:00:00 pm
16.25 USD   +0.81%
10/25INSIDER SELL : Twist Bioscience
MT
10/22BB BIOTECH AG : BB Biotech: i ricavi -2-
DJ
10/22PRESS RELEASE : BB Biotech: Gains realized -2-
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Nektar Therapeutics : Partners With Pfizer, Merck for Clinical Trial

09/21/2021 | 10:53am EDT


ę MT Newswires 2021
All news about NEKTAR THERAPEUTICS
10/25INSIDER SELL : Twist Bioscience
MT
10/22BB BIOTECH AG : BB Biotech: i ricavi -2-
DJ
10/22PRESS RELEASE : BB Biotech: Gains realized -2-
DJ
09/23Redhill Biopharma, AstraZeneca, Nektar Therapeutics Settle Movantik Patent Litigation w..
MT
09/22NEKTAR THERAPEUTICS : Thinking about trading options or stock in Ambarella, Robinhood Mark..
PR
09/21Nektar Therapeutics Shares Rise 5% on Deal With Pfizer, Merck KGaA
DJ
09/21NEKTAR THERAPEUTICS : Partners With Pfizer, Merck for Clinical Trial
MT
09/21NEKTAR THERAPEUTICS : Announces New Clinical Collaboration with Merck KGaA Darmstadt, Germ..
PR
09/21Nektar Announces New Clinical Collaboration with Merck KGaA Darmstadt, Germany and Pfiz..
CI
09/17NEKTAR THERAPEUTICS : Corporate Presentation September 2021
PU
More news
Analyst Recommendations on NEKTAR THERAPEUTICS
More recommendations
Financials (USD)
Sales 2021 109 M - -
Net income 2021 -552 M - -
Net cash 2021 484 M - -
P/E ratio 2021 -5,39x
Yield 2021 -
Capitalization 2 987 M 2 987 M -
EV / Sales 2021 22,9x
EV / Sales 2022 6,88x
Nbr of Employees 718
Free-Float 99,1%
Chart NEKTAR THERAPEUTICS
Duration : Period :
Nektar Therapeutics Technical Analysis Chart | NKTR | US6402681083 | MarketScreener
Technical analysis trends NEKTAR THERAPEUTICS
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 16,25 $
Average target price 29,50 $
Spread / Average Target 81,5%
EPS Revisions
Managers and Directors
Howard W. Robin President, Chief Executive Officer & Director
Gilbert M. Labrucherie Chief Operating & Financial Officer
Robert B. Chess Chairman
Jonathan Zalevsky Chief Research & Development Officer
Dimitry S. A. Nuyten Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
NEKTAR THERAPEUTICS-4.41%2 963
MODERNA, INC.230.95%141 099
LONZA GROUP AG31.93%60 646
IQVIA HOLDINGS INC.42.93%49 145
SEAGEN INC.1.46%31 933
CELLTRION, INC.-38.02%25 328